78.69
price down icon5.27%   -4.38
pre-market  Pre-market:  79.62   0.93   +1.18%
loading
Novo Nordisk Adr stock is traded at $78.69, with a volume of 20.67M. It is down -5.27% in the last 24 hours and down -27.15% over the past month. With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$83.07
Open:
$79.94
24h Volume:
20.67M
Relative Volume:
3.01
Market Cap:
$349.44B
Revenue:
$39.36B
Net Income/Loss:
$13.79B
P/E Ratio:
25.50
EPS:
3.086
Net Cash Flow:
$9.83B
1W Performance:
-8.78%
1M Performance:
-27.15%
6M Performance:
-41.89%
1Y Performance:
-26.24%
1-Day Range:
Value
$78.17
$80.88
1-Week Range:
Value
$78.17
$84.72
52-Week Range:
Value
$78.17
$148.15

Novo Nordisk Adr Stock (NVO) Company Profile

Name
Name
Novo Nordisk Adr
Name
Phone
-
Name
Address
-
Name
Employee
72,000
Name
Twitter
@novonordisk
Name
Next Earnings Date
2024-12-06
Name
Latest SEC Filings
Name
NVO's Discussions on Twitter

Compare NVO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
78.69 349.44B 39.36B 13.79B 9.83B 3.086
Drug Manufacturers - General icon
LLY
Lilly Eli Co
725.72 689.73B 40.86B 8.37B -2.28B 9.25
Drug Manufacturers - General icon
JNJ
Johnson Johnson
147.03 344.63B 87.70B 14.68B 19.03B 6.05
Drug Manufacturers - General icon
ABBV
Abbvie Inc
171.56 303.17B 55.53B 5.12B 15.62B 2.88
Drug Manufacturers - General icon
MRK
Merck Co Inc
97.92 251.88B 63.17B 12.15B 14.84B 4.77

Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-06-25 Upgrade Bernstein Underperform → Mkt Perform
May-30-24 Initiated Goldman Buy
Apr-12-24 Initiated BMO Capital Markets Outperform
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Neutral
Dec-01-23 Initiated Cantor Fitzgerald Overweight
Oct-02-23 Initiated Argus Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-15-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-28-22 Downgrade UBS Neutral → Sell
Jun-27-22 Upgrade Exane BNP Paribas Underperform → Neutral
Jun-07-22 Upgrade JP Morgan Neutral → Overweight
May-31-22 Upgrade Guggenheim Neutral → Buy
Apr-25-22 Upgrade Cowen Market Perform → Outperform
Apr-12-22 Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22 Upgrade Deutsche Bank Hold → Buy
Jan-25-22 Downgrade Liberum Hold → Sell
Dec-20-21 Downgrade JP Morgan Overweight → Neutral
Dec-17-21 Downgrade Deutsche Bank Buy → Hold
Jan-20-21 Downgrade Credit Suisse Outperform → Neutral
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Hold
Jul-06-20 Downgrade BofA Securities Buy → Neutral
May-11-20 Downgrade UBS Buy → Neutral
May-04-20 Initiated Cowen Market Perform
Mar-16-20 Upgrade BofA/Merrill Neutral → Buy
Jan-03-20 Downgrade Guggenheim Buy → Neutral
Nov-18-19 Upgrade Barclays Equal Weight → Overweight
Sep-17-19 Upgrade Citigroup Neutral → Buy
Aug-30-19 Downgrade Jefferies Hold → Underperform
Jun-20-19 Downgrade Deutsche Bank Buy → Hold
Jun-11-19 Upgrade Barclays Underweight → Equal Weight
Apr-29-19 Upgrade Credit Suisse Neutral → Outperform
Jan-29-19 Initiated Exane BNP Paribas Outperform
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Dec-29-17 Upgrade JP Morgan Underweight → Neutral
Dec-06-17 Upgrade BofA/Merrill Neutral → Buy
Dec-01-17 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-25-17 Downgrade Exane BNP Paribas Outperform → Neutral
Sep-06-17 Upgrade BofA/Merrill Underperform → Neutral
View All

Novo Nordisk Adr Stock (NVO) Latest News

pulisher
05:47 AM

Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom? - The Motley Fool

05:47 AM
pulisher
Jan 20, 2025

2 Companies Poised to Capitalize on the Rise of GLP-1 Weight Loss Drugs - Morningstar

Jan 20, 2025
pulisher
Jan 17, 2025

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.

Jan 17, 2025
pulisher
Jan 14, 2025

Is Now The Time To Buy PDD Holdings Inc ADR (NASDAQ: PDD) Stock? - Stocks Register

Jan 14, 2025
pulisher
Jan 14, 2025

Where Do Analysts Think The Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Is Going - Stocks Register

Jan 14, 2025
pulisher
Jan 09, 2025

European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN

Jan 09, 2025
pulisher
Jan 07, 2025

Precidian Investments Builds Out Its ADRhedged ETF Lineup with Four New Strategies, Offering Targeted International Exposure with Integrated Currency Hedge - Business Wire

Jan 07, 2025
pulisher
Dec 31, 2024

Eli Lilly, Novo Nordisk Went Head-to-Head on Weight-Loss Drugs in 2024. There’s a Clear Winner. - Barron's

Dec 31, 2024
pulisher
Dec 31, 2024

Is Alibaba Group Holding Ltd ADR’s (NYSE:BABA) Stock On The Decline? - Stocks Register

Dec 31, 2024
pulisher
Dec 25, 2024

European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading - MSN

Dec 25, 2024
pulisher
Dec 24, 2024

Will Novo Nordisk (NVO) Stock Recover To $145 Levels? - Forbes

Dec 24, 2024
pulisher
Dec 23, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Dec 23, 2024
pulisher
Dec 20, 2024

Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. - Barron's

Dec 20, 2024
pulisher
Dec 20, 2024

Markets News, December 20, 2024: Stocks Rise After Encouraging Inflation Data to Wrap Up Rough Week; Major Indexes Post Weekly Losses - Investopedia

Dec 20, 2024
pulisher
Dec 20, 2024

Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment - Morningstar

Dec 20, 2024
pulisher
Dec 18, 2024

European Equities Traded in the US as American Depositary Fall in Wednesday Trading - MSN

Dec 18, 2024
pulisher
Dec 16, 2024

Novo Nordisk A/S - GlobeNewswire Inc.

Dec 16, 2024
pulisher
Dec 09, 2024

Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue - Barron's

Dec 09, 2024
pulisher
Dec 05, 2024

Lilly Tops Nordisk In Weightloss Battle - Real Investment Advice

Dec 05, 2024
pulisher
Nov 30, 2024

Why Novo Nordisk A/S (NVO) Is the Best ADR Stock to Invest in? - Insider Monkey

Nov 30, 2024
pulisher
Nov 29, 2024

12 Best ADR Stocks To Invest In According to Analysts - Insider Monkey

Nov 29, 2024
pulisher
Nov 28, 2024

NVO Stock Quote Price and Forecast - CNN

Nov 28, 2024
pulisher
Nov 27, 2024

European Equities Traded in the US as American Depositary Decline in Tuesday Trading - MSN

Nov 27, 2024
pulisher
Nov 20, 2024

Novo Nordisk ADR (NYSE: NVO) Could Fell Another -55.9% - Stocks Register

Nov 20, 2024
pulisher
Nov 20, 2024

Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets

Nov 20, 2024

Novo Nordisk Adr Stock (NVO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$147.03
price down icon 0.50%
$171.56
price down icon 1.23%
drug_manufacturers_general MRK
$97.92
price down icon 2.76%
drug_manufacturers_general NVS
$97.53
price down icon 0.34%
drug_manufacturers_general PFE
$26.30
price down icon 0.72%
Cap:     |  Volume (24h):